Sustained Release Excipients Market

Sustained Release Excipients Market Size, Market Forecast and Outlook by Fact.MR

• The sustained release excipients market was valued at USD 1.5 billion in 2025.
• Demand is estimated to reach USD 1.7 billion in 2026 and is projected to rise to USD 4.0 billion by 2036.
• The market is forecast to record 8.9% CAGR from 2026 to 2036 as controlled drug delivery and chronic therapy use support demand.
• Sustained release excipient demand is rising as drug formulators need controlled release profiles for chronic therapies.
• These excipients help reduce dosing and make treatment easier for patients.

Summary of sustained release excipients market

• Demand Drivers in the Market
  • Controlled Dosing: Formulators need excipients that release drugs slowly over time. This supports medicines used for chronic treatments.
  • Compliance Need: Pharmaceutical companies use sustained release systems to reduce dosing frequency. This can improve patient adherence.
  • Quality Assurance: CDMOs need qualified excipients with reliable documentation. Supplier consistency helps protect scale-up work.
• Key Segments Analyzed
  • By Product: Polymers are projected to record 42.0% share in 2026 as matrix tablets and coatings rely on release-control polymer systems.
  • By Route of Administration: Oral routes lead because tablets and capsules remain the main format for sustained release therapy. The route is estimated to hold 52.0% share in 2026.
  • By Technology: Targeted delivery is projected to account for 28.0% share in 2026 as formulators need release profiles aligned with therapeutic need.
  • By Dosage Form: Tablets lead because hydrophilic matrix and coated tablet systems remain widely used. The dosage form is expected to hold 44.0% share in 2026.
  • By End User: Pharmaceutical manufacturers are anticipated to represent 54.0% share in 2026 because in-house formulation programs drive excipient selection.
  • By Geography: China sustained release excipients demand is forecast to grow at 6.7% CAGR from 2026 to 2036 as advanced formulation and domestic drug manufacturing expand.
• Analyst Opinion at Fact.MR
  • Shambhu Nath Jha, Senior Analyst at Fact.MR, states, “Sustained release excipients are no longer passive formulation aids. They decide how reliably a therapy performs across dosing intervals. Suppliers that prove release consistency, regulatory documentation and batch reliability will gain stronger traction with drug developers.”
• Strategic Implications
  • Release Control: Excipient suppliers need clear technical data and consistent grades. Poor release performance can delay formulation approval.
  • Supplier Qualification: Pharmaceutical manufacturers should check excipient sources early. Late supplier changes can disrupt development timelines.
  • Scale-up Support: CDMOs need materials that transfer smoothly from lab batches to commercial production. Weak process fit raises reformulation risk.

Formulation work is shifting from simple release delay to planned release control. This supports demand for excipients that help developers achieve predictable release and consistent product quality.

China is forecast to grow at 6.7% CAGR from 2026 to 2036 as domestic drug manufacturing and advanced formulation work expand. South Korea is projected to record 6.4% CAGR through pharmaceutical innovation and CDMO activity. United States demand is set to rise at 6.3% CAGR as controlled-release generics and formulation upgrades continue. Germany follows at 6.2% CAGR through excipient quality standards and drug delivery research. Japan is likely to post 6.2% CAGR as aging care supports long-acting dosage forms.

Segmental Analysis

Sustained Release Excipients Market Analysis by Product

Polymers are projected to hold 42.0% share in 2026 because matrix systems and functional coatings need predictable release control. Gelatin supports capsule and soft delivery formats. Minerals help with compressibility and selected release functions. Sugars and chitosan serve narrower formulation needs. Polymers lead because formulators need materials that manage swelling and diffusion. Troches-Mafla, Salamanca and Ciro stated in 2025 that modified-release systems use diffusion and swelling mechanisms. They also noted that diffusion-controlled systems move drugs through a polymeric matrix or semi-permeable membrane. [1]

• Polymer Control: Polymers regulate drug diffusion and matrix behavior. Poor grade selection can shift the release profile.
• Mineral Support: Minerals help tablet structure and process stability. Their role is supportive rather than dominant.
• Chitosan Use: Chitosan supports selected bioadhesive and specialty systems. It needs careful compatibility review before scale-up.

Sustained Release Excipients Market Analysis by Route of Administration

Oral routes lead because tablets and capsules remain the main formats for long-acting medicines. Injectable depots serve therapies that need extended drug exposure without daily dosing. Transdermal systems support steady drug delivery through the skin. The oral route is estimated to hold 52.0% share in 2026 as solid dosage products use matrix and pellet-based release designs. Oral sustained release is preferred because patients can take medicines without devices or clinical visits. Injectable and transdermal routes are useful in therapies that need tighter release control.

• Oral Base: Oral dosage forms support tablets and capsules. This keeps formulation scale broad.
• Depot Delivery: Injectable depots support longer exposure windows. Development needs stronger compatibility and release testing.
• Skin Route: Transdermal systems provide controlled delivery through skin. Adhesion and release behavior must stay consistent.

Sustained Release Excipients Market Analysis by Technology

Targeted delivery is projected to hold 28.0% share in 2026 as formulators design release behavior around therapy needs and absorption sites. Microencapsulation supports protected drug release and controlled particle systems. Wurster technique, implants and coacervation serve more specialized development routes. Targeted delivery leads because drug developers need excipients that improve active ingredient use and reduce systemic exposure. Uzakova et al. stated in 2025 that advanced drug delivery systems support targeted delivery and controlled release, with reduced systemic toxicity as a key goal. [2]

• Targeted Release: Targeted delivery supports controlled exposure at the desired site. Strong design can reduce formulation waste.
• Encapsulation Need: Microencapsulation protects sensitive actives and manages release. Process control is critical during scale-up.
• Wurster Coating: Wurster systems support coated particles and pellets. Uniform coating affects release performance.

Sustained Release Excipients Market Analysis by Dosage Form

Tablets lead because matrix and coated tablet systems are widely used in sustained release drug development. Capsules support multiparticulate and pellet-filled delivery. Injectable depots serve long-acting therapies. Transdermal systems support controlled delivery outside the gastrointestinal route. The tablet dosage form is expected to hold 44.0% share in 2026 because it supports scalable production and familiar patient use. Tablets stay ahead because manufacturing lines and regulatory pathways are well understood. Newer dosage forms can add value, but they need tighter development control.

• Matrix Tablets: Matrix systems support controlled release through polymer swelling and diffusion. Release consistency depends on grade selection.
• Pellet Capsules: Capsules can carry coated multiparticulates. They help formulators combine dose flexibility with controlled release.
• Depot Forms: Injectable depots serve longer therapy windows. Release testing and sterility demands raise development complexity.

Sustained Release Excipients Market Analysis by End User

Pharmaceutical manufacturers are expected to hold 54.0% share in 2026 because in-house drug programs guide excipient selection and qualification. CDMOs support demand through formulation development and manufacturing transfer. Nutraceutical producers use selected sustained release systems, but their regulatory needs are lighter than pharmaceuticals. Research laboratories support early-stage screening. Pharmaceutical manufacturers lead because they carry greater responsibility for product safety and documentation. CDMOs gain demand as complex formulation work moves outside sponsor companies.

• Pharma Ownership: Pharmaceutical companies control formulation strategy and supplier approval. This keeps them central to demand.
• CDMO Scale-up: CDMOs support development transfer and commercial batches. Reliable excipient behavior reduces rework.
• Research Screening: Laboratories test new release systems and compatibility. Early results shape later material choice.

Sustained Release Excipients Market Drivers, Restraints, and Opportunities

Chronic therapy needs and patient adherence are the main demand drivers. Sustained release excipients help formulators reduce dosing frequency and keep drug release steadier over time. They also help formulation scientists assess route-specific use and development risk.

Excipient qualification and regulatory documentation are the main restraints. Modified-release products need strong proof because release failure can affect efficacy or safety. Quality requirements can slow adoption of novel excipients or unfamiliar release systems.

Opportunities in the Sustained Release Excipients Market

• Polymer Matrix Systems: Suppliers can support oral tablets through HPMC and methacrylate-based materials. Consistent grades help formulators protect release performance.
• Long-acting Injectables: Drug developers can use biodegradable and lipid-based excipients for depot systems. Testing support remains critical.
• CDMO Partnerships: CDMOs can gain work through formulation transfer and scale-up support.

Regional Analysis

Based on regional analysis, the sustained release excipients market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East and Africa.

Source: Fact.MR analysis based on forecast model and primary research.

Asia Pacific Sustained Release Excipients Market Analysis

Asia Pacific demand comes from pharmaceutical manufacturing expansion and advanced formulation investment. China leads through domestic drug production and release-control technology adoption. South Korea supports growth through innovation-led pharmaceutical development. Japan adds steady demand through long-term therapy needs and aging care. The region rewards suppliers that combine material performance with regulatory documentation.

• China: China is forecast to grow at 6.7% CAGR from 2026 to 2036 as domestic drug manufacturing and advanced formulation work increase. Formulators need polymers and coating systems for controlled release in generics and specialty medicines. Local manufacturers are improving drug delivery capability. NMPA published State Council opinions in March 2025 that call for China to shift from a major pharmaceutical manufacturer to a pharmaceutical powerhouse and improve generic drug quality through stronger review and inspection. [3] Suppliers with application support and reliable documentation can gain better access to formulation programs.
• South Korea: South Korea pharmaceutical innovation base supports demand for sustained release excipient. Drug developers and CDMOs need materials that help create differentiated release profiles. Sustained release excipients in South Korea are forecast to grow at 6.4% CAGR over the assessment period. Supplier selection will depend on technical support and formulation testing because developers need faster development cycles.
• Japan: Japan aging population supports demand for medicines that reduce dosing burden. Sustained release excipients demand in Japan is forecast to grow at 6.2% CAGR over the forecast period. Suppliers with stable grades and Japan-ready documents can protect demand.

North America Sustained Release Excipients Market Analysis

North America demand is led by controlled-release generics and advanced formulation work. The United States leads because FDA pathways and a large pharmaceutical base shape excipient use. Developers need excipients with route-specific history and clear technical support. Supplier strength depends on regulatory confidence and scale-up assistance.

• United States: Controlled-release generics and formulation upgrades support sustained release excipient demand in the United States. Sustained release excipients demand in the United States is forecast to grow at 6.3% CAGR by 2036. FDA’s April 2026 Inactive Ingredients Database download includes route, dosage form, CAS number, UNII and potency data. FDA also updates the database quarterly. [4] Suppliers with strong documents and application labs can protect higher-value accounts.

Europe Sustained Release Excipients Market Analysis

Europe demand is supported by excipient quality standards and advanced oral formulation work. Germany support strong demand through pharmaceutical manufacturing and specialty drug development. European developers place high value on GMP and supplier traceability. Suppliers need strong documentation and technical support.

• Germany: Excipient quality standards and drug delivery research support sustained release excipient demand in Germany. The market is forecast to grow at 6.2% CAGR through 2036. Pharmaceutical companies need sustained release excipients for oral solids and coatings. Demand will favor suppliers with strong batch traceability and clear technical documents.

Competitive Aligners for Market Players

The sustained release excipients market includes specialty chemical suppliers, pharmaceutical excipient producers and drug delivery technology companies. BASF competes through Kollicoat coating polymers and oral dosage excipients. Evonik competes through EUDRAGIT functional polymers for controlled release. IFF supports cellulose-based excipients through METHOCEL. Ashland competes through specialty pharmaceutical ingredients. Croda, Gattefossé and Merck KGaA support lipid, polymer and formulation-grade excipient demand.

Supplier position will rely on formulation support through 2036. Pharmaceutical manufacturers need excipients that can pass quality review. CDMOs need materials that transfer across development and commercial batches. Research laboratories need dependable grades for early screening. Companies that combine polymer chemistry, application testing and quality documentation can protect repeat demand.

Key Players in Sustained Release Excipients Market

• BASF SE
• Roquette Health & Pharma Solutions
• Ashland Global Holdings Inc.
• Evonik Industries AG
• Croda International Plc
• Colorcon Inc.

Bibliography

• [1] Troches-Mafla, E., Salamanca, C. H., & Ciro, Y. (2025). Controlled release technologies for diltiazem hydrochloride: A comprehensive review of solid dosage innovations.
• [2] Uzakova, A. B., Yergaliyeva, E. M., Yerlanuly, A., & Mukatayeva, Z. S. (2025, December 22). A systematic review of advanced drug delivery systems: Engineering strategies, barrier penetration, and clinical progress (2016–April 2025). Pharmaceutics, 18(1), 11.  
• [3] National Medical Products Administration. (2025, March 25). Opinions of the General Office of the State Council on comprehensively deepening the reform of regulation of drugs and medical devices to promote the high-quality development of the pharmaceutical industry.
• [4] Food and Drug Administration. (2026, April 13). Inactive Ingredients Database Download. U.S. Food and Drug Administration.

This Report Addresses

• Strategic intelligence on sustained release excipient demand across polymers and functional coatings.
• Growth opportunity mapping across China and South Korea plus the United States and Germany.
• Segment analysis by product, route of administration, technology, dosage form and end user.
• Regional outlook covering controlled-release formulation, excipient quality and drug delivery innovation.
• Competitive analysis of BASF SE, Roquette Health & Pharma Solutions, Ashland Global Holdings Inc., Evonik Industries AG, Croda International Plc, Colorcon Inc.
• Product assessment covering polymers, oral routes, targeted delivery and tablet dosage forms.
• Market forecast built from Fact.MR’s baseline model with a revised 2026 to 2036 CAGR.
• Primary interviews, supplier checks and excipient regulatory source review support validation.

Sustained Release Excipients Market Definition

The sustained release excipients market covers inactive pharmaceutical materials used to control the release of active ingredients over time. The scope includes polymers and other functional excipients used in matrix tablets and transdermal systems. The market differs from general excipients because its main role is release modulation rather than simple tablet binding or bulk filling.

Sustained Release Excipients Market Inclusions

The scope includes gelatin and chitosan used in sustained release systems. Oral and transdermal routes are covered. Targeted delivery and microencapsulation technologies are included. Tablets and pellets are counted if the excipient controls drug release. Pharmaceutical manufacturers and CDMOs are included as major users.

Sustained Release Excipients Market Exclusions

The scope excludes excipients used only for immediate release products. General binders and colors are outside scope when they do not regulate release. Active pharmaceutical ingredients are excluded. Finished drugs are not counted as excipients. Packaging materials and medical devices are outside scope unless they are part of a drug delivery system requiring sustained release excipient design.

Sustained Release Excipients Market Research Methodology

• Primary Research
  • Primary research includes interviews with formulation scientists and pharmaceutical development heads. CDMO technical managers were reviewed for scale-up needs. Quality assurance specialists were checked for excipient qualification and supplier validation.
• Desk Research
  • Desk research reviewed excipient regulatory sources and modified-release guidance. Company product pages supported polymer and coating validation. Pharmacopoeial and GMP sources helped review quality expectations.
• Market-Sizing and Forecasting
  • Forecasting uses product demand and route of administration. Technology estimates reflect formulation complexity and controlled-release adoption. End-user estimates are linked to pharmaceutical production and CDMO formulation work.
• Data Validation and Update Cycle
  • Forecasts were validated through excipient supplier checks and regulatory source review. Regional assumptions were reviewed with formulation activity and pharmaceutical manufacturing depth. Supplier evidence supported the competitive view.